{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:19:23Z","timestamp":1781421563317,"version":"3.54.1"},"reference-count":22,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":4476,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Venlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the efficacy, safety and tolerability of venlafaxine ER in treating panic disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Adult out-patients (<jats:italic>n<\/jats:italic>=361) with panic disorder were randomly assigned to receive venlafaxine ER (75\u2013225 mg\/day) or placebo for up to 10 weeks in a double-blind study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Venlafaxine ER was not associated with a greater proportion of patients free from full-symptom panic attacks at the finalon-therapy evaluation, but was associated with lower mean panic attack frequency and a higher proportion free from limited-symptom panic attacks, higher response and remission rates, and improvements in anticipatory anxiety, fear and avoidance. Adverse events were comparable with those of the drug in depression and anxiety disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Venlafaxine ER seems to be effective and well tolerated in the short-term treatment of panic disorder.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.187.4.352","type":"journal-article","created":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T22:58:05Z","timestamp":1128121085000},"page":"352-359","source":"Crossref","is-referenced-by-count":77,"title":["Venlafaxine extended-release capsules in panic disorder"],"prefix":"10.1192","volume":"187","author":[{"given":"Jacques","family":"Bradwejn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Ahokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliseo","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Emilien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000168060_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90769-0"},{"key":"S0007125000168060_ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000168060_ref10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1209"},{"key":"S0007125000168060_ref2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S0007125000168060_ref13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0805"},{"key":"S0007125000168060_ref6","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000168060_ref15","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700608"},{"key":"S0007125000168060_ref19","volume-title":"The Anxiety Disease","author":"Sheehan","year":"1983"},{"key":"S0007125000168060_ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.602"},{"key":"S0007125000168060_ref16","first-page":"667","article-title":"Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study","volume":"32","author":"Pollack","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000168060_ref18","first-page":"4","article-title":"The road to recovery in panic disorder: response, remission, and relapse","volume":"59","author":"Shear","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000168060_ref3","first-page":"47","article-title":"Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety","volume":"59","author":"Ballenger","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000168060_ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199506000-00004"},{"key":"S0007125000168060_ref5","first-page":"30","article-title":"Pharmcotherapy of panic disorder: differential efficacy from a clinical viewpoint","volume":"59","author":"den Boer","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000168060_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.23.3082"},{"key":"S0007125000168060_ref8","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0007125000168060_ref11","first-page":"69","article-title":"Differentiating anxiety and depression in anxiety disorders: use of rating scales","volume":"18","author":"Lipman","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000168060_ref14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.1989"},{"key":"S0007125000168060_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(02)00010-9"},{"key":"S0007125000168060_ref20","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000168060_ref21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.180.5.396"},{"key":"S0007125000168060_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(03)00235-X"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000168060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T20:03:07Z","timestamp":1556913787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000168060\/type\/journal_article"}},"subtitle":["Flexible-dose, double-blind, placebo-controlled study"],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0007125000168060"],"URL":"https:\/\/doi.org\/10.1192\/bjp.187.4.352","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}